Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex
Advertisement
Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a drug-drug interaction study with simeprevir and VX-135 to support the planned initiation of a phase II proof-of-concept study in early 2013, pending discussions with regulatory authorities.
The phase II study is expected to evaluate safety, tolerability and viral cure rates using a 12-week combination of simeprevir and VX-135, with and without ribavirin. Janssen and Vertex will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.
Simeprevir is a potent, once-daily investigational hepatitis C protease inhibitor, currently in phase III trials, being jointly developed by Medivir AB and Janssen R&D Ireland.VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase.
“This study will broaden our understanding of simeprevir, which we believe has the necessary characteristics to become a key component of future hepatitis C treatment regimens, including combination with interferon and ribavirin as well as interferon-free therapies and is in line with Medivir’s and Janssen’s strategy to evaluate different interferon-free HCV treatment possibilities” comments Charlotte Edenius, EVP of Research and Development, Medivir AB.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Stora Enso enters into strategic partnership with Swedish University of Agricultural Sciences
Images of NMDA receptors help explain how they are affected by zinc and a drug
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
